At present, 安尼可® is the only PD-1 monoclonal antibody that applies the immunoglobulin G1 (‘‘IgG1’’) subtype modified by the fragment crystallizable (Fc) segment in the world, which has a lower antigen binding off-rate and a unique binding epitope as demonstrated by analysis on crystal structure. These features allow 安尼可® to effectively and continuously block PD-1/PD-L1 binding, thus differentiating it from PD-1 products on the market, and may enable安尼可® to more effectively enhance immunotherapeutic efficacy and reduce immune-related adverse reactions. The main indications for安尼可® include lung cancer, liver cancer, gastric cancer, nasopharyngeal cancer, esophageal cancer, classical Hodgkin’s lymphoma, mesothelioma, thymic cancer, urothelial cancer, bile duct cancer and neuroendocrine cancer. Currently,  phase III clinical studies on 安尼可® plus Anlotinib in the first-line treatment of non-phosphorous non-small cell lung cancer, liver cancer and gastric cancer, have all entered the final stage.